Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Traditional medicines have and will continue to form the basis of modern pharmaceuticals. Many indigenous communities are claiming rights in pharmaceuticals derived from their traditional medicine. In the past, such knowledge derived from non-western communities was largely regarded as free information. This has led some to attack the patent system as an ex-ploitative tool of the developed world. The first part of this analysis deals with the kind of protection provided in national legislation. Methods of protecting traditional medicine in India and China receive special attention. The second major issue covered in this volume is the kind of protection offered to TM of other countries in the west, including international agreements. America is a particular focus, as it is here that many of the battles over patenting traditional medicine are fought. While no uncon-troversial answers can be given in this debate, at least the relative strengths and weaknesses of various positions can be assessed. Dr. Murray Eiland received a doctorate in Oriental Archaeology from Oxford University and an LLM from the Munich Intellectual Property Law Center. He currently works at Charles Henry & Co., London as a (non-practising) Barrister.
Choose an application
"This book is an outcome of a partnership between the Max Planck Institute (MPI) for Innovation and Competition and the South Centre, which jointly organized a Global Forum on Intellectual Property, Access to Medicine and Innovation in Munich on 9-10 December 2019"--Page v
Patent medicines --- Law and legislation --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs --- Drugs, Nonprescription --- access to medicines --- TRIPS --- Intellectual Property Exhaustion --- Compulsory license --- Pharmaceutical Patents --- genome editing --- Open Access
Choose an application
Brazil
Patent medicines --- Drugs --- Law and legislation --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs, Nonprescription --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Brazilian Patent Provisions --- brasilianischen Patentrechts --- Gewerblicher Rechtsschutz
Choose an application
This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
Patent medicines --- Drugs --- Law and legislation --- Economic aspects --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs, Nonprescription --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Gewerblicher Rechtsschutz
Choose an application
"Across the world, developing countries are attempting to balance the international standards of intellectual property concerning pharmaceutical patents against the urgent need for accessible and affordable medicines. In this timely and necessary book, Monirul Azam examines the attempts of several developing countries to walk this fine line. He evaluates the experiences of Brazil, China, India, and South Africa for lessons to guide Bangladesh and developing nations everywhere. Azam's legal expertise, concern for public welfare, and compelling grasp of principal case studies make Intellectual Property and Public Health in the Developing World a definitive work. The developing world is striving to meet the requirements of the World Trade Organization's TRIPS Agreement on intellectual property. This book sets out with lucidity and insight the background of the TRIPS Agreement and its implications for pharmaceutical patents, the consequences for developing countries, and the efforts of certain representative nations to comply with international stipulations while still maintaining local industry and public health. Azam then brings the weight of this research to bear on the particular case of Bangladesh, offering a number of specific policy recommendations for the Bangladeshi government--and for governments the world over. Intellectual Property and Public Health in the Developing World is a must-read for public policy-makers, academics and students, non-governmental organizations, and readers everywhere who are interested in making sure that developing nations meet the health care needs of their people."-- Publisher's website.
Patent medicines --- Drug accessibility --- Pharmaceutical industry --- Pharmaceutical policy. --- Intellectual property --- Intellectual property (International law) --- Law and legislation --- Cost control. --- International law --- Drug policy --- Drugs --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- Drug industry --- Drug trade --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Chemical industry --- Access to drugs --- Accessibility of drugs --- Availability of drugs --- Drug availability --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs, Nonprescription --- Government policy
Listing 1 - 5 of 5 |
Sort by
|